Latest News
& Press Releases

A new study published in the BMJ found strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.

Gilead’s stock traded lower on news that claims will proceed that allege the company delayed the development of newer, safer HIV drugs in order to maximize profits.

For experts on Boston Consulting Group’s generative AI panel, effectively using the technology in the biotech industry will be a collaborative process.

Triumvira Immunologics’ president and chief operating officer Rob Williamson noted that cell therapy companies might still have an uphill battle unless they can differentiate.

Clarivate’s latest Drug to Watch list highlights new modalities shaping drug development, including gene editing and artificial intelligence.

The Massachusetts–based startup will use the Series A funds to advance its pipeline of oral GPR17, CSF1R and TYK2 candidates.

On Sunday, ahead of the J.P. Morgan Healthcare Conference, Alphabet’s artificial intelligence startup Isomorphic Labs secured its first pharma partnerships with Eli Lilly and Novartis worth nearly $3 billion.

Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.

The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.

As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.

The affiliate of the Multidisciplinary Association for Psychedelic Studies launched the fundraising effort to support its New Drug Application for an investigational, MDMA-assisted therapy for post-traumatic stress disorder.

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments